Dr. Petros Grivas from Fred Hutchinson Cancer Center shares what data he’s most looking forward to discussing at the bladder cancer panel during the second annual Uromigos: Live & Unplugged event taking place in Nashville, Tennessee on November 3rd and 4th, along with this favorite moments from the Uromigos podcast.
Advertisement
Latest News
Patients considering PC screening should talk to their PCP or urologist about the benefits and risks of identifying PC early.
Dr. McKay discusses upcoming prostate cancer data to be presented at ESMO and discussed at The Uromigos: Live & Unplugged.
Dr. Gupta also discusses upcoming bladder cancer data from ESMO that will influence debate and discussion at the event.
Patients with a complete resection at pcRPLND and <10% viable cells had favorable outcomes without any further treatment.
Bladder cancers that develop after radiation tend to be more aggressive and are more likely to be sarcomatoid variant.
Higher tumor fraction after chemohormonal therapy was also linked to aggressive pathologic features and poor outcomes.
The novel nomogram demonstrated perfect performance in discrimination ability and clinical net benefit.
The phase 3 KEYNOTE-A39/EV-302 study has met its dual primary end points of OS and PFS in advanced or metastatic UC.
The FDA has accepted for priority review the sNDA for belzutifan in patients who were previously treated for advanced RCC.
Dr. de Kouchkovsky highlights survival and response rates after ICIs and EV for patients with squamous histology.
Dr. de Kouchkovsky explains studying the impact of squamous histology on clinical outcomes in mUC after ICIs or EV.
AUA Amendment to Testicular Cancer Guideline Includes New Treatment Options, Imaging Recommendations
The AUA released a new amendment to their 2019 guideline for the diagnosis and treatment of early-stage testicular cancer.Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Catherine H. Marshall, MD, MPHEditor | Assistant Professor of Oncology at the Johns Hopkins University School of Medicine
Jérémie Calais, MD, MScEditor | Director of the Theranostics and Clinical Research Programs at the University of California, Los Angeles
Akhil Abraham Saji, MDAssociate Editor | Fellow at the University of Southern California
David Ambinder, MDAssociate Editor | Urology Resident at New York Medical College/Westchester Medical Center
Expert Interviews
Hans Hammers, MD, PhD – Driving Immunotherapy Combinations Into the Modern Age of Kidney Cancer Care
Dr. Hammers discusses the kidney clinical trials he has led and shares his perspectives on novel IO and targeted therapies.
Dr. Sonpavde expounds on the current state and momentum of research efforts to advance treatment strategies in MIBC.
Dr. Siefker-Radtke shares the novel targeted therapies for bladder cancer and how they are assessed in combinations.
Dr. Msaouel shares his journey to becoming a world expert in RMC and the clinical trial work he led to improve outcomes.
Katherine Virgo, PhD, MBA, provided insight into ASCO's updated guideline for the management of metastatic prostate cancer.
Michigan Urological Surgery and Improvement Collaborative is an effort to improve patient lives through high-quality care.
Knowledge Hubs
Curated clinical content based on conditions, therapies, and technologies
GU Oncology Now delivers the latest news in clinical trials, conference coverage, and more, highlighting advancements in genitourinary oncology treatments and tech.
Get research and breaking news straight to your inbox.
The Uromigos
Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD
Conference Coverage
Live meeting highlights
Dr. McKay discusses upcoming prostate cancer data to be presented at ESMO and discussed at The Uromigos: Live & Unplugged.
Dr. Gupta also discusses upcoming bladder cancer data from ESMO that will influence debate and discussion at the event.
The second annual Uromigos: Live & Unplugged event will take place in Nashville, Tennessee, on November 3-4.
Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.
Video Insights
Clinical discussions with experts in the field
